The role of innate and lymphoid IL-22-producing cells in the immunopathology of primary Sjögren's syndrome

Expert Review of Clinical Immunology

Volumn 10, Issue 4, 2014, Pages 533-541

  Ciccia, Francesco ^a   Guggino, Giuliana ^a   Giardina, Annarita ^a   Ferrante, Angelo ^a   Carrubbi, Francesco ^b   Giacomelli, Roberto ^b   Triolo, Giovanni ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

adaptive immunity; epithelial cells; IL 22; innate immunity; NK cells; primary Sj grens syndrome

Indexed keywords

INTERLEUKIN 22;

ADAPTIVE IMMUNITY; CYTOKINE PRODUCTION; EPITHELIUM CELL; GENE OVEREXPRESSION; HUMAN; IMMUNOPATHOGENESIS; IMMUNOPATHOLOGY; INFLAMMATION; INNATE IMMUNITY; LYMPHOID CELL; NATURAL KILLER CELL; NONHUMAN; PERMEABILITY BARRIER; REVIEW; SJOEGREN SYNDROME;

ADAPTIVE IMMUNITY; HUMANS; IMMUNITY, INNATE; INTERLEUKINS; KILLER CELLS, NATURAL; SJOGREN'S SYNDROME;

EID: 84896935759     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2014.884461     Document Type: Review

References (91)

1. Talal N, Sylvester RA, Daniels TE, et al. T and B lymphocytes in peripheral blood and tissue lesions in Sjogren's syndrome. J Clin Invest 1974;53(1):180-9
2. Mavragani CP, Moutsopoulos HM. Sjogren's Syndrome. Annu Rev Pathol 2013. [Epub ahead of print]
3. Liang Y, Yang Z, Qin B, Zhong R. Primary Sjogren's syndrome and malignancy risk: a systematic review and meta-analysis. Ann Rheum Dis 2013. [Epub ahead of print]
4. Ohyama Y, Nakamura S, Matsuzaki G, et al. Cytokine messenger RNA expression in the labial salivary glands of patients with Sjogren's syndrome. Arthritis Rheum 1996; 39(8):1376-84
5. Fox RI, Kang HI, Ando D, et al. Cytokine mRNA expression in salivary gland biopsies of Sjogren's syndrome. J Immunol 1994; 152(11):5532-9
6. van Woerkom JM, Kruize AA, Wenting-van Wijk MJ, et al. Salivary gland and peripheral blood T helper 1 and 2 cell activity in Sjogren's syndrome compared with non-Sjogren's sicca syndrome. Ann Rheum Dis 2005;64(10):1474-9
7. Katsifis GE, Rekka S, Moutsopoulos NM, et al. Systemic and local interleukin-17 and linked cytokines associated with Sjogren's syndrome immunopathogenesis. Am J Pathol 2009;175(3):1167-77
8. Nguyen CQ, Hu MH, Li Y, et al. Salivary gland tissue expression of interleukin-23 and interleukin-17 in Sjogren's syndrome: findings in humans and mice. Arthritis Rheum 2008;58(3):734-43
9. Moutsopoulos HM, Chused TM, Johnson AH, et al. B lymphocyte antigens in sicca syndrome. Science 1978;199(4336): 1441-2
10. Groom J, Kalled SL, Cutler AH, et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J Clin Invest 2002; 109(1):59-68
11. Rusakiewicz S, Nocturne G, Lazure T, et al. NCR3/NKp30 contributes to pathogenesis in primary Sjogren's syndrome. Sci Transl Med 2013;5(195):195ra196
12. Manoussakis MN, Dimitriou ID, Kapsogeorgou EK, et al. Expression of B7 costimulatory molecules by salivary gland epithelial cells in patients with Sjogren's syndrome. Arthritis Rheum 1999; 42(2):229-39
13. Xanthou G, Polihronis M, Tzioufas AG, et al. "Lymphoid" chemokine messenger RNA expression by epithelial cells in the chronic inflammatory lesion of the salivary glands of Sjogren's syndrome patients: possible participation in lymphoid structure formation. Arthritis Rheum 2001;44(2): 408-18
14. Barone F, Bombardieri M, Rosado MM, et al. CXCL13, CCL21, and CXCL12 expression in salivary glands of patients with Sjogren's syndrome and MALT lymphoma: association with reactive and malignant areas of lymphoid organization. J Immunol 2008; 180(7):5130-40
15. Sugimoto K, Ogawa A, Mizoguchi E, et al. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J Clin Invest 2008;118(2):534-44
16. Aujla SJ, Chan YR, Zheng M, et al. IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. Nat Med 2008;14(3):275-81
17. Ciccia F, Accardo-Palumbo A, Alessandro R, et al. Interleukin-22 and IL-22-producing NKp44(+) NK cells in the subclinical gut inflammation of patients with ankylosing spondylitis. Arthritis Rheum 2012;64(6): 1869-78
18. Ikeuchi H, Kuroiwa T, Hiramatsu N, et al. Expression of interleukin-22 in rheumatoid arthritis: potential role as a proinflammatory cytokine. Arthritis Rheum 2005;52(4): 1037-46
19. Bard JD, Gelebart P, Anand M, et al. Aberrant expression of IL-22 receptor 1 and autocrine IL-22 stimulation contribute to tumorigenicity in ALK+ anaplastic large cell lymphoma. Leukemia 2008;22(8): 1595-603
20. Gelebart P, Zak Z, Dien-Bard J, et al. Interleukin 22 signaling promotes cell growth in mantle cell lymphoma. Transl Oncol 2011;4(1):9-19
21. Rutz S, Eidenschenk C, Ouyang W. IL-22, not simply a Th17 cytokine. Immunol Rev 2013;252(1):116-32
22. Sonnenberg GF, Nair MG, Kirn TJ, et al. Pathological versus protective functions of IL-22 in airway inflammation are regulated by IL-17A. J Exp Med 2010;207(6): 1293-305
23. Lavoie TN, Stewart CM, Berg KM, et al. Expression of interleukin-22 in Sjogren's syndrome: significant correlation with disease parameters. Scand J Immunol 2011; 74(4):377-82
24. Ciccia F, Guggino G, Rizzo A, et al. Potential involvement of IL-22 and IL-22-producing cells in the inflamed salivary glands of patients with Sjogren's syndrome. Ann Rheum Dis 2012;71(2): 295-301
25. Ouyang W, Rutz S, Crellin NK, et al. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol 2011;29: 71-109
26. Dumoutier L, Van Roost E, Colau D, Renauld JC. Human interleukin-10- related T cell-derived inducible factor: molecular cloning and functional characterization as an hepatocyte-stimulating factor. Proc Natl Acad Sci USA 2000;97(18):10144-9
27. Xie MH, Aggarwal S, Ho WH, et al. Interleukin (IL)-22, a novel human cytokine that signals through the interferon receptor-related proteins CRF2-4 and IL-22R. J Biol Chem 2000;275(40): 31335-9
28. Kotenko SV, Izotova LS, Mirochnitchenko OV, et al. Identification of the functional interleukin-22 (IL-22) receptor complex: the IL-10R2 chain (IL- 10Rbeta) is a common chain of both the IL-10 and IL-22 (IL-10-related T cell-derived inducible factor, IL-TIF) receptor complexes. J Biol Chem 2001; 276(4):2725-32
29. Wolk K, Kunz S, Witte E, et al. IL-22 increases the innate immunity of tissues. Immunity 2004;21(2):241-54
30. Le'cart S, Morel F, Noraz N, et al. IL-22, in contrast to IL-10, does not induce Ig production, due to absence of a functional IL-22 receptor on activated human B cells. Int Immunol 2002;14(11):1351-6
31. Nagalakshmi ML, Rascle A, Zurawski S, et al. Interleukin-22 activates STAT3 and induces IL-10 by colon epithelial cells. Int Immunopharmacol 2004;4(5):679-91
32. Lejeune D, Dumoutier L, Constantinescu S, et al. Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line. Pathways that are shared with and distinct from IL-10. J Biol Chem 2002;277(37): 33676-82
33. Dumoutier L, Lejeune D, Colau D, Renauld JC. Cloning and characterization of IL-22 binding protein, a natural antagonist of IL-10-related T cell-derived inducible factor/IL-22. J Immunol 2001;166(12): 7090-5
34. Huber S, Gagliani N, Zenewicz LA, et al. IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine. Nature 2012;491(7423):259-63
35. Dinarello CA, Novick D, Kim S, Kaplanski G. Interleukin-18 and IL-18 Binding Protein. Front Immunol 2013;4:289
36. Bombardieri M, Barone F, Pittoni V, et al. Increased circulating levels and salivary gland expression of interleukin-18 in patients with Sjogren's syndrome: relationship with autoantibody production and lymphoid organization of the periductal inflammatory infiltrate. Arthritis Res Ther 2004;6(5):R447-56
37. Gurney AL. IL-22, a Th1 cytokine that targets the pancreas and select other peripheral tissues. Int Immunopharmacol 2004;4(5):669-77
38. Sutton CE, Lalor SJ, Sweeney CM, et al. Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity. Immunity 2009;31(2): 331-41
39. Zheng Y, Danilenko DM, Valdez P, et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007;445(7128):648-51
40. Wolk K, Kunz S, Asadullah K, Sabat R. Cutting edge: immune cells as sources and targets of the IL-10 family members? J Immunol 2002;168(11):5397-402
41. Liang SC, Tan XY, Luxenberg DP, et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 2006;203(10):2271-9
42. Duhen T, Geiger R, Jarrossay D, et al. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol 2009;10(8):857-63
43. Trifari S, Kaplan CD, Tran EH, et al. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat Immunol 2009;10(8):864-71
44. Ortega C, Ferna'ndez-A S, Carrillo JM, et al. IL-17-producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines. J Leukoc Biol 2009; 86(2):435-43
45. Martin B, Hirota K, Cua DJ, et al. Interleukin-17-producing gammadelta T cells selectively expand in response to pathogen products and environmental signals. Immunity 2009;31(2):321-30
46. Goto M, Murakawa M, Kadoshima-Yamaoka K, et al. Murine NKT cells produce Th17 cytokine interleukin-22. Cell Immunol 2009;254(2):81-4
47. Doisne JM, Soulard V, Be'court C, et al. Cutting edge: crucial role of IL-1 and IL-23 in the innate IL-17 response of peripheral lymph node NK1.1- invariant NKT cells to bacteria. J Immunol 2011; 186(2):662-6
48. Crellin NK, Trifari S, Kaplan CD, et al. Human NKp44+IL-22+ cells and LTi-like cells constitute a stable RORC+ lineage distinct from conventional natural killer cells. J Exp Med 2010;207(2):281-90
49. Cupedo T, Crellin NK, Papazian N, et al. Human fetal lymphoid tissue-inducer cells are interleukin 17-producing precursors to RORC+ CD127+ natural killer-like cells. Nat Immunol 2009;10(1):66-74
50. Cella M, Fuchs A, Vermi W, et al. A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature 2009;457(7230):722-5
51. Ahn YO, Blazar BR, Miller JS, Verneris MR. Lineage relationships of human interleukin-22-producing CD56+ RORgt+ innate lymphoid cells and conventional natural killer cells. Blood 2013;121(12):2234-43
52. Qiu J, Guo X, Chen ZM, et al. Group 3 innate lymphoid cells inhibit T-cell-mediated intestinal inflammation through aryl hydrocarbon receptor signaling and regulation of microflora. Immunity 2013;39(2):386-99
53. Zelante T, Iannitti RG, Cunha C, et al. Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-Immunity 2013;39(2):372-85
54. Leppkes M, Becker C, Ivanov II, et al. RORgamma-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F. Gastroenterology 2009;136(1):257-67
55. Wolk K, Witte E, Wallace E, et al. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol 2006;36(5):1309-23
56. Boniface K, Guignouard E, Pedretti N, et al. A role for T cell-derived interleukin 22 in psoriatic skin inflammation. Clin Exp Immunol 2007;150(3):407-15
57. Zheng Y, Valdez PA, Danilenko DM, et al. Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat Med 2008;14(3):282-9
58. Liang SC, Nickerson-Nutter C, Pittman DD, et al. IL-22 induces an acute-phase response. J Immunol 2010; 185(9):5531-8
59. Croxford AL, Mair F, Becher B. IL-23: one cytokine in control of autoimmunity. Eur J Immunol 2012;42(9):2263-73
60. Ghoreschi K, Laurence A, Yang XP, et al. T helper 17 cell heterogeneity and pathogenicity in autoimmune disease. Trends Immunol 2011;32(9):395-401
61. Glatzer T, Killig M, Meisig J, et al. RORgt+ innate lymphoid cells acquire a proinflammatory program upon engagement of the activating receptor NKp44. Immunity 2013;38(6):1223-35
62. Savan R, McFarland AP, Reynolds DA, et al. A novel role for IL-22R1 as a driver of inflammation. Blood 2011;117(2):575-84
63. Ciccia F, Alessandro R, Rizzo A, et al. Expression of interleukin-32 in the inflamed arteries of patients with giant cell arteritis. Arthritis Rheum 2011;63(7):2097-104
64. Eun YG, Shin IH, Lee YC, et al. Interleukin 22 polymorphisms and papillary thyroid cancer. J Endocrinol Invest 2013; 36(8):584-7
65. Thompson CL, Plummer SJ, Tucker TC, et al. Interleukin-22 genetic polymorphisms and risk of colon cancer. Cancer Causes Control 2010;21(8):1165-70
66. Beyeen AD, Adzemovic MZ, Ockinger J, et al. IL-22RA2 associates with multiple sclerosis and macrophage effector mechanisms in experimental neuroinflammation. J Immunol 2010; 185(11):6883-90
67. Endam LM, Bossé Y, Filali-Mouhim A, et al. Polymorphisms in the interleukin-22 receptor alpha-1 gene are associated with severe chronic rhinosinusitis. Otolaryngol Head Neck Surg 2009;140(5):741-7
68. Suh JS, Cho SH, Chung JH, et al. A polymorphism of interleukin-22 receptor alpha-1 is associated with the development of childhood IgA nephropathy. J Interferon Cytokine Res 2013;33(10):571-7
69. Meijer JM, Meiners PM, Vissink A, et al. Effectiveness of rituximab treatment in primary Sjogren's syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010;62(4):960-8
70. Pijpe J, van Imhoff GW, Spijkervet FK, et al. Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study. Arthritis Rheum 2005;52(9): 2740-50
71. Ciccia F, Giardina A, Rizzo A, et al. Rituximab modulates the expression of IL-22 in the salivary glands of patients with primary Sjogren's syndrome. Ann Rheum Dis 2013;72(5):782-3
72. Long EO, Kim HS, Liu D, et al. Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu Rev Immunol 2013;31: 227-58
73. Hughes T, Becknell B, Freud AG, et al. Interleukin-1beta selectively expands and sustains interleukin-22+ immature human natural killer cells in secondary lymphoid tissue. Immunity 2010;32(6):803-14
74. Kumar P, Thakar MS, Ouyang W, Malarkannan S. IL-22 from conventional NK cells is epithelial regenerative and inflammation protective during influenza infection. Mucosal Immunol 2013;6(1): 69-82
75. Dhiman R, Indramohan M, Barnes PF, et al. IL-22 produced by human NK cells inhibits growth of Mycobacterium tuberculosis by enhancing phagolysosomal fusion. J Immunol 2009;183(10):6639-45
76. Li H, Ice JA, Lessard CJ, Sivils KL. Interferons in Sjogren's Syndrome: genes, Mechanisms, and Effects. Front Immunol 2013;4:290
77. Nguyen CQ, Peck AB. The Interferon- Signature of Sjogren's Syndrome: how Unique Biomarkers Can Identify Underlying Inflammatory and Immunopathological Mechanisms of Specific Diseases. Front Immunol 2013;4:142
78. Minato N, Takeda A, Kano S, Takaku F. Studies of the function of natural killer-interferon system in patients with Sjogren syndrome. J Clin Invest 1982;69(3): 581-8
79. Miyasaka N, Seaman W, Bakshi A, et al. Natural killing activity in Sjogren's syndrome. An analysis of defective mechanisms. Arthritis Rheum 1983;26(8): 954-60
80. Pedersen BK, Oxholm P, Manthorpe R, Andersen V. Interleukin 2 augmentation of the defective natural killer cell activity in patients with primary Sjogren's syndrome. Clin Exp Immunol 1986;63(1):1-7
81. Takeda A, Minato N, Kano S. Selective impairment of alpha-interferon- mediated natural killer augmentation in Sjogren's syndrome: differential effects of alphainterferon, gamma-interferon, and interleukin 2 on cytolytic activity. Clin Exp Immunol 1987;70(2):354-63
82. Izumi Y, Ida H, Huang M, et al. Characterization of peripheral natural killer cells in primary Sjogren's syndrome: impaired NK cell activity and low NK cell number. J Lab Clin Med 2006;147(5): 242-9
83. Vivier E, Biron CA. Immunology. A pathogen receptor on natural killer cells. Science 2002;296(5571):1248-9
84. Vitale M, Della Chiesa M, Carlomagno S, et al. NK-dependent DC maturation is mediated by TNFalpha and IFNgamma released upon engagement of the NKp30 triggering receptor. Blood 2005; 106(2):566-71
85. Okuma A, Hoshino K, Ohba T, et al. Enhanced apoptosis by disruption of the STAT3-IkB-z signaling pathway in epithelial cells induces Sjogren's syndrome-like autoimmune disease. Immunity 2013;38(3):450-60
86. Baker OJ. Tight junctions in salivary epithelium. J Biomed Biotechnol 2010;2010:278948
87. Guillot C, Lecuit T. Mechanics of epithelial tissue homeostasis and morphogenesis. Science 2013;340(6137):1185-9
88. Shen L, Weber CR, Raleigh DR, et al. Tight junction pore and leak pathways: a dynamic duo. Annu Rev Physiol 2011;73: 283-309
89. Ewert P, Aguilera S, Alliende C, et al. Disruption of tight junction structure in salivary glands from Sjogren's syndrome patients is linked to proinflammatory cytokine exposure. Arthritis Rheum 2010; 62(5):1280-9
90. Odusanwo O, Chinthamani S, McCall A, et al. Resolvin D1 prevents TNF-a-mediated disruption of salivary epithelial formation. Am J Physiol Cell Physiol 2012;302(9):C1331-45
91. Goicovich E, Molina C, Pe'rez P, et al. Enhanced degradation of proteins of the basal lamina and stroma by matrix metalloproteinases from the salivary glands of Sjogren's syndrome patients: correlation with reduced structural integrity of acini and ducts. Arthritis Rheum 2003;48(9): 2573-84